Professor Michal Novak enters a new position in AXON Neuroscience, the new CSO was named Assoc. Prof. Norbert Zilka
1.10.2015 07:41 | Business Wire
Biotech company AXON Neuroscience, which is currently a driving force in the development of disease modifying treatments for Alzheimer’s disease(AD), is pleased to announce that Prof. Michal Novak, has been appointed as a Chairman of the Scientific Advisory Board of AXON Neuroscience , effective from October 1, 2015. Assoc. Prof. Norbert Zilka, previously AXON’s Head of Preclinical Trials, was named the company’s new Chief Science Officer.
„Prof. Novak is the author of ground-breaking discoveries, which were essential for new approaches in the development of the disease modifying treatment of AD. His vision sets the course not only for our company, but based on the recent development of AD therapeutic approaches, for the whole industry. We are delighted that he will continue to support AXON Neuroscience from his new position, which will leave him more space to focus on developing new products and making AXON‘s portfolio stronger and more diversified,“ said Roman Sivak, AXON’s CEO, after the Board meeting.
Professor Michal Novak co-discovered the main component of neurofibrillary degeneration, a key element of Alzheimer’s disease. He spent 10 years working at the Laboratory of molecular Biology, MRC in Cambridge in a team with three Nobel laureates Sir Aaron Klug, Cesar Milstein and John Walker. In 1999 he co-founded a biotech company AXON Neuroscience. Prof. Novak also founded the Institute of Neuroimmunology of the Slovak Academy of Sciences (SAV), the Memory foundation, the Slovak Alzheimer’s Association, and the Slovak Society for Neuroscience. In addition, he is a co-founder of the largest global research initiative aimed at tackling the challenges of neurodegenerative diseases – Joint Programming on Neurodegenerative Disorders.
As the Head of Preclinical Trials, Assoc. Prof. Norbert Zilka was previously responsible for creating novel animal models for human neurodegenerative disorders and preclinical development of immunotherapeutics. He is the author of the tau immunological cascade in Alzheimer’s disease. Assoc. Prof. Zilka was a national coordinator of Biomarkers for Alzheimer’s disease and Parkinson’s disease, a project running under the Joint Programming Neurodegenerative Disease grant scheme. He is also a co-author of the project Synaptic Dysfunction in Alzheimer’s Disease funded by Marie Sklodowska-Curie Innovative Training Network and was a national coordinator and chairman of the Neuroscience session at the first Frontiers of Science Meeting organized by the Royal Society and V4 countries in 2010. Norbert Zilka has been working with Prof. Novak since the foundation of the company in 1999 and played the key role in the leading discoveries, which he further helped to transform into AXON‘s portfolio of products.
+421 902 161 362
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Altierre Strengthens Executive Team in Europe With Hiring of Guillaume Vicot and Niclas Qvist22.8.2017 12:00 | Pressemelding
Altierre Corp., a provider of the world’s highest density, ultra-low energy, long-range wireless technology and applications for the Internet of Things (IoT) market, today announced two additions to its France-based European executive team. Guillaume Vicot has joined the company as General manager, Europe, Middle East and Asia (EMEA) and Niclas Qvist has joined as Vice President, Partner management & Marketing. Vicot joins Altierre’s management team after 17 successful years in the Auto-ID industry, barcode scanning and mobile computing. He most recently served as Vice President of sales, Western Europe, for PSC / Datalogic, leader in the bar code scanning industry, where he oversaw a team of more than 100 people and developed a tactical go-to-market strategy, achieving revenue well over US$100 million. “Guillaume has many top level strategic relationships with retailers
IFF to Present at the Barclays Global Consumer Staples Conference21.8.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, today announced that Andreas Fibig, Chairman and Chief Executive Officer will present at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7, 2017 at 11:15 a.m. EDT. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for explorati
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform21.8.2017 20:11 | Pressemelding
Celularity, Inc., a newly formed biotechnology company, today announced its acceleration of cell and tissue regenerative therapies to address unmet medical needs in cancer and chronic and degenerative disease. Celularity completed their Series A financing with contributions from several biopharma companies, including Sorrento Therapeutics, United Therapeutics Corporation and Human Longevity, Inc., and entrepreneurial investors. Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including: Several clinical-stage immuno-oncology and regenerative medicine assets and a pipeline of pre-clinical assets Proprietary allogeneic (“readily accessible”) immunotherapy platform 200+ issued and pending patents in cell therapy
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25 | Pressemelding
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00 | Pressemelding
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03 | Pressemelding
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom